Proscia: Getting to Know Kary Rogers: A Conversation with Proscia’s Head of Support

From Proscia on LinkedIn When evaluating an enterprise pathology platform, many life sciences organizations and diagnostic laboratories focus on the features it offers. This makes sense since scientists and pathologists will rely on that...

Bioptimus to use Cancer Research Horizons’ data to train and evaluate its AI foundation model Third partnership since Bioptimus launched ground-breaking STELA initiative in March Deal adds Bioptimus' first UK patient cohort to...

Imagene AI: Integration with Proscia’s Concentriq platform will facilitate pharma companies, diagnostic assay and platform providers, and CROs in operationalizing companion diagnostic programs August 18, 2026  Imagene AI, a leader in...

Nucleai, Gilead, and target-positive tumors Antibody-drug conjugates (ADCs) have emerged as one of the busiest and most crowded niches within oncology, given their potential to use an antibody to ferry a potent cytotoxic payload toward...

Lumea: Company Recognized for Large Revenue Growth, Earning a Place Among the Nation’s Most Successful Independent Businesses LEHI, UT, UNITED STATES, August 11, 2026 /EINPresswire/ — Lumea today announced it has been ranked No. 1,641 on...

aetherAI: Delivering Integrated Software-and-Hardware Consulting Solutions for the Global Digital Transformation of Pathology — Growth Momentum Poised to Accelerate aetherAI (7803), a global leader in digital pathology and AI healthcare...